Latest News

Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.
Inavolisib Combo Receives EU Approval in PIK3CA+ ER+/HER2– Breast Cancer

July 24th 2025

Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.

No Breast Cancer Events Noted When Breastfeeding After ET in HR+ Disease
No Breast Cancer Events Noted When Breastfeeding After ET in HR+ Disease

July 20th 2025

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.
T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer

July 18th 2025

Strategizing ADC Use to Enhance Breast Cancer Outcomes
Strategizing ADC Use to Enhance Breast Cancer Outcomes

July 17th 2025